Antiviral therapy for COVID-19
DOI: 10.32364/2587-6821-2023-7-11-8
Yu.A. Larchenko1,2, O.Yu. Agapova2, G.G. Mar'in3, O.E. Vakhrushkina1, M.V. Kukharenok1, S.Yu. Nistor1, T.F. Guseva2, E.A. Medvedeva3, K.A. Zykov2,4
1E.O. Mukhin City Clinical Hospital, Moscow, Russian Federation
2A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
3RUDN University, Moscow, Russian Federation
4Research Institute of Pulmonology of the Federal Medical Biological Agency of Russia, Moscow, Russian Federation
This article reviews data on the incidence of ARVIs and novel coronavirus infection (COVID-19) in the Russian Federation and key antiviral therapies for ARVI and discusses recent published data on the use of various antivirals for COVID-19 treatment, with particular attention to potential biological drug targets. Data from several studies on the broad-spectrum antiviral drug riamilovir are addressed. Riamilovir was found to be highly effective with good tolerability and a favorable safety profile. The range of antiviral activity of riamilovir has significantly expanded over the past few years. In particular, this drug can be used for both the treatment and prevention of COVID-19. Riamilovir was approved by the Russian Ministry of Health not only for ARVI but also for COVID-19 infection and was included in the Clinical Protocol for the inpatient treatment of patients with COVID-19 admitted to Moscow public health system medical institutions. Moreover, riamilovir is also included in the Standard for the diagnosis and treatment of novel coronavirus infection in military personnel of the Armed Forces of the Russian Federation as an etiologic agent of choice for COVID-19 treatment.
Keywords: antiviral therapy, riamilovir, ARVI, influenza, SARS-CoV-2, COVID-19.
For citation: Larchenko Yu.A., Agapova O.Yu., Mar'in G.G., Vakhrushkina O.E., Kukharenok M.V., Nistor S.Yu., Guseva T.F., Medvedeva E.A., Zykov K.A. Antiviral therapy for COVID-19. Russian Medical Inquiry. 2023;7(11):759–765 (in Russ.). DOI: 10.32364/2587-6821-2023-7-11-8.
Yuliya A. Larchenko — Head of the Department of Pulmo-nology, E.O. Mukhin City Clinical Hospital; 17, Federativnyy av., Moscow, 111399, Russian Federation; senior laboratory assistant of the Department of the of the Faculty Therapy and Occupational Diseases of the N.A. Semashko Scientific Educational Institution of Clinical Medicine; A.I. Yevdokimov Moscow State University of Medicine and Dentistry; 4, Dolgorukovskaya str., Moscow, 127006, Russian Federation.
Olga Yu. Agapova — C. Sc. (Med.), associate professor of the Department of the of the Faculty Therapy and Occupational Diseases of the N.A. Semashko Scientific Educational Institution of Clinical Medicine; A.I. Yevdokimov Moscow State University of Medicine and Dentistry; 4, Dolgorukovskaya str., Moscow, 127006, Russian Federation.
German G. Mar'in — Dr. Sc. (Med.), Associate Professor, professor of the Department of Epidemiology, RUDN University; 6, Miklukho-Maklaya str., Moscow, 117198, Russian Federation; ORCID iD 0000-0003-2179-8421.
Olga E. Vakhrushkina — C. Sc. (Med.), pulmonologist of the Department of Pulmonology, E.O. Mukhin City Clinical Hospital; 17, Federativnyy av., Moscow, 111399, Russian Federation.
Mariya V. Kukharenok — pulmonologist of the Department of Pulmonology, E.O. Mukhin City Clinical Hospital; 17, Federativnyy av., Moscow, 111399, Russian Federation.
Svetlana Yu. Nistor — functional diagnostics doctor of the Department of Pulmonology, E.O. Mukhin City Clinical Hospital; 17, Federativnyy av., Moscow, 111399, Russian Federation.
Tatyana F. Guseva — C. Sc. (Med.), associate professor of the Department of the of the Faculty Therapy and Occupational Diseases of the N.A. Semashko Scientific Educational Institution of Clinical Medicine; A.I. Yevdokimov Moscow State University of Medicine and Dentistry; 4, Dolgorukovskaya str., Moscow, 127006, Russian Federation.
Evgeniya A. Medvedeva — C. Sc. (Med.), assistant of the Department of Propaedeutics of Internal Diseases and Gastroenterology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry; 4, Dolgorukovskaya str., Moscow, 127006, Russian Federation; ORCID iD 0000-0001-7786-3777.
Kirill A. Zykov — Dr. Sc. (Med.), Corresponding Member of the RAS, Professor of the RAS, Deputy Director for Scientific and Innovative Work, Research Institute of Pulmonology of the Federal Medical Biological Agency of Russia; 28, Orekhovyy blvrd., Moscow, 115682, Russian Federation; Head of the Department of the of the Faculty Therapy and Occupational Diseases of the N.A. Semashko Scientific Educational Institution of Clinical Medicine; A.I. Yevdokimov Moscow State University of Medicine and Dentistry; 4, Dolgorukovskaya str., Moscow, 127006, Russian Federation; ORCID iD 0000-0003-3385-2632.
Contact information: Olga Yu. Agapova, e-mail: o.yu.agapova@ya.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 05.09.2023.
Revised 28.09.2023.
Accepted 23.10.2023.
References
1. Jevšnik, M., Uršič, T., Žigon, N. et al. Coronavirus infections in hospitalized pediatric patients with acute respiratory tract disease. BMC Infect Dis. 2012;12:365. DOI: 10.1186/1471-2334-12-365.
2. Зыков К.А., Синицын Е.А., Рвачева А.В. и др. Обоснование нового алгоритма амбулаторной лекарственной терапии пациентов с COVID-19, основанного на принципе множественных воздействий. Антибиотики и химиотерапия. 2021;66(3–4):49–61. DOI: 10.37489/0235-2990-2021-66-3-4-49-61. [Zykov K.A., Sinitsyn E.A., Rvacheva A.V. et al. Substantiation of a new algorithm for outpatient drug therapy of patients with COVID-19 based on the principle of multiple exposures. Antibiotiki i khimioterapiya. 2021;66(3-4):49–61 (in Russ.)]. DOI: 10.37489/0235-2990-2021-66-3-4-49-61.
3. Schulz T.F., Falke D. Antivirale Chemotherapie. In: Suerbaum S., Hahn H., Burchard G.D. et al., eds. Medizinische Mikrobiologie und Infektiologie. Springer-Lehrbuch. Springer, Berlin, Heidelberg. DOI: 10.1007/978-3-642-24167-3_108.
4. Ong C.W., Migliori G.B., Raviglione M. et al. Epidemic and pandemic viral infections: Impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J. 2020;56(4):2001727. DOI: 10.1183/13993003.01727-2020.
5. Huang D., Yu H., Wang T. et al. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2021;93(1):481–490. DOI: 10.1002/jmv.26256.
6. Khamis F., Al Naabi H., Al Lawati A. et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis. 2021;(102):538–543. DOI: 10.1016/j.ijid.2020.11.008.
7. Shah P.L., Orton C.M., Grinsztejn B. et al.; PIONEER trial group. Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): A multicentre, open-label, phase 3, randomized controlled trial of early intervention versus standard care. Lancet Respir Med. 2022:S2213-2600(22)00412-X. DOI: 10.1016/S2213-2600(22)00412-X.
8. Coomes E.A., Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother. 2020;75(7):2013–2014. DOI: 10.1093/jac/dkaa171.
9. Cao B., Wang Y., Wen D. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. DOI: 10.1056/NEJMoa2001282.
10. Beckerman R., Gori A., Jeyakumar S. et al. Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: A targeted literature review and meta-analysis. Sci Rep. 2022;12(1):9622. DOI: 10.1038/s41598-022-13680-6.
11. Анциферов М.Б., Аронов Л.С., Белевский А.С. и др. Клинический протокол лечения больных новой коронавирусной инфекцией (COVID-19), находящихся на стационарном лечении в медицинских организациях государственной системы здравоохранения города Москвы. Под ред. А.И. Хрипуна. М.; 2020. [Antsiferov M.B., Aronov L.S., Belevsky A.S. et al. Clinical protocol for the treatment of patients with a new coronavirus infection (COVID-19) who are on inpatient treatment in medical organizations of the state healthcare system of the city of Moscow. Khripun A.I., ed. Moscow; 2020 (in Russ.)].
12. Khaitov M., Nikonova A., Shilovskiy I. et al. Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation. Allergy. 2021;76(9):2840–2854. DOI: 10.1111/all.14850.
13. Lai C.C., Wang Y.H., Chen K.H. et al. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: A systematic review and network meta-analysis of randomized controlled trials. Viruses. 2022;14(8):1706. DOI: 10.3390/v14081706.
14. Тихонова Е.П., Кузьмина Т.Ю., Андронова Н.В. и др. Изучение эффективности противовирусных препаратов (умифеновира, триазавирина) в отношении острых респираторных вирусных инфекций. Казанский медицинский журнал. 2018;99(2):215–223. DOI: 10.17816/KMJ2018-215. [Tikhonova E.P., Kuz'mina T.Y., Andronova N.V. et al. Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections. Kazan Medical Journal. 2018;99(2):215–223 (in Russ.)]. DOI: 10.17816/KMJ2018-215.
15. Киселев О.И., Деева Э.Г., Мельникова Т.И. и др. Новый противовирусный препарат Триазавирин. Результаты II фазы клинического исследования. Вопросы вирусологии. 2012;57(6):9–12. [Kiselev O.I., Deyeva E.G., Melnicova T.I., Kozeletskaia K.N., Kiselev A.S., Rusinov V.L. et al. A new antiviral drug triazavirin: results of phase II clinical trial. Problems of Virology. 2012;57(6):9–12 (in Russ.)].
16. Веревщиков В.К., Шемякина Е.К., Сабитов А.У., Бацкалевич Н.А. Современная этиотропная терапия гриппа и ОРВИ у взрослых больных с отягощенной преморбидной патологией. Антибиотики и химиотерапия. 2018;63(7–8):47–50. [Verevshchikov V.K., Shemyakina E.K., Sabitov A.U., Batskalevich N.A. Modern Etiotropic Therapy of Influenza and ARVI in Adult Patients with Premorbid Pathology. Antibiotics and Chemotherapy. 2018;63(7–8):47–50 (in Russ.)].
17. Токин И.И., Зубкова Т.Г., Дроздова Ю.В., Лиознов Д.А. Опыт этиотропной терапии ОРВИ отечественным противовирусным препаратом. Инфекционные болезни. 2019;17(4):13–17. DOI: 10.20953/1729-9225-2019-4-13-1. [Tokin I.I., Zubkova T.G., Drozdova Y.V., Lioznov D.A. Experience of etiotropic therapy of acute respiratory viral infection with domestic antiviral drug. Infectious Diseases. 2019;17(4):13–17 (in Russ.)]. DOI: 10.20953/1729-9225-2019-4-13-1.
18. Касьяненко К.В., Львов Н.И., Мальцев О.В., Жданов К.В. Нуклеозидные аналоги в терапии гриппа: история и опыт. Журнал инфектологии. 2019;11(3):20–26. DOI: 10.22625/2072-6732-2019-11-3-20-26. [Kasianenko K.V., Lvov N.I., Maltsev O.V., Zhdanov K.V. nucleoside analogues for the treatment of influenza: history and experience. Journal Infectology. 2019;11(3):20–26 (in Russ.)]. DOI: 10.22625/2072-6732-2019-11-3-20-26.
19. Rusinov V.L., Sapozhnikova I.M., Ulomskii E.N. et al. Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine-containing proteins. Chemistry of Heterocyclic Compounds. 2015;51(3):275–280. DOI: 10.1007/s10593-015-1695-4.
20. Чупахин О.Н., Русинов В.Л., Уломский Е.Н. и др. Способ получения натриевой соли 2-метилтио-6-нитро-1,2-4-триазоло[5,1-с]-1,2,4-триазин-7-она, дигидрата, обладающей противовирусной активностью. Патент RU2343154C2. Опубл. 10.01.2009. [Chupakhin O.N., Rusinov V.L., Ulomskij E.N. et al. 2-Methylthio-6-nitro-1,2,4-triazolo[5,1-c]-1,2,4-triazine-7(4H)-one sodium salt dehydrate possessing antiviral activity. Patent RU2343154C2. Published 01.10.2009 (in Russ.)].
21. Wu X., Yu K., Wang Y. et al. Efficacy and safety of triazavirin. Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial. Engineering (Beijing). 2020;6(10):1185–1191. DOI: 10.1016/j.eng.2020.08.011.
22. Сабитов А.У., Белоусов В.В., Един А.С. и др. Практический опыт применения препарата риамиловир в лечении пациентов с COVID-19 средней степени тяжести. Антибиотики и химиотерапия. 2020;65(7–8):27–30. DOI: 10.37489/0235-2990-2020-65-7-8-27-30. [Sabitov A.U., Belousov V.V., Odin A.S. et al. Practical experience of using the drug Riamilovir in the treatment of patients with COVID-19 of moderate severity. Antibiotiki i khimioterapiya. 2020;65(7–8):27–30 (in Russ.)]. DOI: 10.37489/0235-2990-2020-65-7-8-27-30.
23. Сабитов А.У., Сорокин П.В., Дашутина С.Ю. Эффективность и безопасность применения препарата Риамиловир в лечении пациентов с COVID-19. Антибиотики и химиотерапия. 2021;66(1-2):35–37. DOI: 10.37489/0235-2990-2021-66-1-2-33-37. [Sabitov А.U., Sorokin Р.V., Dashutina S.U. The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19. Antibiotics and Chemotherapy. 2021;66(1-2):35–37 (in Russ.)]. DOI: 10.37489/0235-2990-2021-66-1-2-33-37.
24. Сабитов А.У., Сорокин П.В., Дашутина С.Ю. Опыт профилактического применения препарата Риамиловир в очагах коронавирусной инфекции (COVID-19). Терапевтический архив. 2021;93(4):435–439. DOI: 10.26442/00403660.2021.04.200751. [Sabitov A.U., Sorokin P.V., Dashutina S.Yu. Experience of the preventive use of the drug Riamilovir in the foci of coronavirus infection (COVID-19) Terapevticheskii Arkhiv (Ter Arkh.). 2021;93(4):435–43 (in Russ.)]. DOI: 10.26442/00403660.2021.04.200751.
25. Анциферов М.Б., Аронов Л.С., Белевский А.С. и др. Клинический протокол лечения больных новой коронавирусной инфекцией (COVID-19), находящихся на стационарном лечении в медицинских организациях государственной системы здравоохранения города Москвы. Под ред. А.И. Хрипуна. М.: ГБУ «НИИОЗММ ДЗМ»; 2020. [Antsiferov M.B., Aronov L.S., Belevsky A.S. and others. Clinical protocol for the treatment of patients with a new coronavirus infection (COVID-19) undergoing inpatient treatment in medical organizations of the state healthcare system of the city of Moscow. Khripun A.I., ed. M.: State Budgetary Institution "NIIOZMM DZM"; 2020 (in Russ.)].
26. Мальцев О.В., Касьяненко К.В., Козлов К.В. и др. Перспективы использования нуклеозидного аналога риамиловира в лечении пациентов с инфекцией, вызванной SARS-CoV-2. Терапевтический архив. 2022;94(10):1171–1176. DOI: 10.26442/00403660.2022.10.201920. [Maltsev O.V., Kasyanenko K.V., Kozlov K.V. et al. Prospects of using the nucleoside analogue riamilovir in patients with SARS-CoV-2 infection. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(10):1171–1176 (in Russ.)]. DOI: 10.26442/00403660.2022.10.201920.
27. Касьяненко К.В., Мальцев О.В., Козлов К.В. и др. Клиническая эффективность и безопасность применения Риамиловира при лечении пациентов с инфекцией, вызванной SARS-CoV-2. Антибиотики и химиотерапия. 2020;65(11-12):16–21. [Kasyanenko K.V., Maltsev O.V., Kozlov K.V. et al. Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection. Antibiotics and Chemotherapy. 2020;65(11–12):16–21 (in Russ.)]. DOI: 10.37489/0235-2990-2020-65-11-12-16-21.
28. Касьяненко К.В., Козлов К.В., Мальцев О.В. и др. Оценка эффективности риамиловира в комплексной терапии больных COVID-19. Терапевтический архив. 2021;93(3):292–296. DOI: 10.26442/00403660.2021.03.200719. [Kasyanenko K.V., Kozlov K.V., Maltsev O.V. et al. Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19. Terapevticheskii Arkhiv (Ter Arkh). 2021;93(3):290–294 (in Russ.)]. DOI: 10.26442/00403660.2021.03.200719.
2. Зыков К.А., Синицын Е.А., Рвачева А.В. и др. Обоснование нового алгоритма амбулаторной лекарственной терапии пациентов с COVID-19, основанного на принципе множественных воздействий. Антибиотики и химиотерапия. 2021;66(3–4):49–61. DOI: 10.37489/0235-2990-2021-66-3-4-49-61. [Zykov K.A., Sinitsyn E.A., Rvacheva A.V. et al. Substantiation of a new algorithm for outpatient drug therapy of patients with COVID-19 based on the principle of multiple exposures. Antibiotiki i khimioterapiya. 2021;66(3-4):49–61 (in Russ.)]. DOI: 10.37489/0235-2990-2021-66-3-4-49-61.
3. Schulz T.F., Falke D. Antivirale Chemotherapie. In: Suerbaum S., Hahn H., Burchard G.D. et al., eds. Medizinische Mikrobiologie und Infektiologie. Springer-Lehrbuch. Springer, Berlin, Heidelberg. DOI: 10.1007/978-3-642-24167-3_108.
4. Ong C.W., Migliori G.B., Raviglione M. et al. Epidemic and pandemic viral infections: Impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J. 2020;56(4):2001727. DOI: 10.1183/13993003.01727-2020.
5. Huang D., Yu H., Wang T. et al. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2021;93(1):481–490. DOI: 10.1002/jmv.26256.
6. Khamis F., Al Naabi H., Al Lawati A. et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis. 2021;(102):538–543. DOI: 10.1016/j.ijid.2020.11.008.
7. Shah P.L., Orton C.M., Grinsztejn B. et al.; PIONEER trial group. Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): A multicentre, open-label, phase 3, randomized controlled trial of early intervention versus standard care. Lancet Respir Med. 2022:S2213-2600(22)00412-X. DOI: 10.1016/S2213-2600(22)00412-X.
8. Coomes E.A., Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother. 2020;75(7):2013–2014. DOI: 10.1093/jac/dkaa171.
9. Cao B., Wang Y., Wen D. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. DOI: 10.1056/NEJMoa2001282.
10. Beckerman R., Gori A., Jeyakumar S. et al. Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: A targeted literature review and meta-analysis. Sci Rep. 2022;12(1):9622. DOI: 10.1038/s41598-022-13680-6.
11. Анциферов М.Б., Аронов Л.С., Белевский А.С. и др. Клинический протокол лечения больных новой коронавирусной инфекцией (COVID-19), находящихся на стационарном лечении в медицинских организациях государственной системы здравоохранения города Москвы. Под ред. А.И. Хрипуна. М.; 2020. [Antsiferov M.B., Aronov L.S., Belevsky A.S. et al. Clinical protocol for the treatment of patients with a new coronavirus infection (COVID-19) who are on inpatient treatment in medical organizations of the state healthcare system of the city of Moscow. Khripun A.I., ed. Moscow; 2020 (in Russ.)].
12. Khaitov M., Nikonova A., Shilovskiy I. et al. Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation. Allergy. 2021;76(9):2840–2854. DOI: 10.1111/all.14850.
13. Lai C.C., Wang Y.H., Chen K.H. et al. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: A systematic review and network meta-analysis of randomized controlled trials. Viruses. 2022;14(8):1706. DOI: 10.3390/v14081706.
14. Тихонова Е.П., Кузьмина Т.Ю., Андронова Н.В. и др. Изучение эффективности противовирусных препаратов (умифеновира, триазавирина) в отношении острых респираторных вирусных инфекций. Казанский медицинский журнал. 2018;99(2):215–223. DOI: 10.17816/KMJ2018-215. [Tikhonova E.P., Kuz'mina T.Y., Andronova N.V. et al. Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections. Kazan Medical Journal. 2018;99(2):215–223 (in Russ.)]. DOI: 10.17816/KMJ2018-215.
15. Киселев О.И., Деева Э.Г., Мельникова Т.И. и др. Новый противовирусный препарат Триазавирин. Результаты II фазы клинического исследования. Вопросы вирусологии. 2012;57(6):9–12. [Kiselev O.I., Deyeva E.G., Melnicova T.I., Kozeletskaia K.N., Kiselev A.S., Rusinov V.L. et al. A new antiviral drug triazavirin: results of phase II clinical trial. Problems of Virology. 2012;57(6):9–12 (in Russ.)].
16. Веревщиков В.К., Шемякина Е.К., Сабитов А.У., Бацкалевич Н.А. Современная этиотропная терапия гриппа и ОРВИ у взрослых больных с отягощенной преморбидной патологией. Антибиотики и химиотерапия. 2018;63(7–8):47–50. [Verevshchikov V.K., Shemyakina E.K., Sabitov A.U., Batskalevich N.A. Modern Etiotropic Therapy of Influenza and ARVI in Adult Patients with Premorbid Pathology. Antibiotics and Chemotherapy. 2018;63(7–8):47–50 (in Russ.)].
17. Токин И.И., Зубкова Т.Г., Дроздова Ю.В., Лиознов Д.А. Опыт этиотропной терапии ОРВИ отечественным противовирусным препаратом. Инфекционные болезни. 2019;17(4):13–17. DOI: 10.20953/1729-9225-2019-4-13-1. [Tokin I.I., Zubkova T.G., Drozdova Y.V., Lioznov D.A. Experience of etiotropic therapy of acute respiratory viral infection with domestic antiviral drug. Infectious Diseases. 2019;17(4):13–17 (in Russ.)]. DOI: 10.20953/1729-9225-2019-4-13-1.
18. Касьяненко К.В., Львов Н.И., Мальцев О.В., Жданов К.В. Нуклеозидные аналоги в терапии гриппа: история и опыт. Журнал инфектологии. 2019;11(3):20–26. DOI: 10.22625/2072-6732-2019-11-3-20-26. [Kasianenko K.V., Lvov N.I., Maltsev O.V., Zhdanov K.V. nucleoside analogues for the treatment of influenza: history and experience. Journal Infectology. 2019;11(3):20–26 (in Russ.)]. DOI: 10.22625/2072-6732-2019-11-3-20-26.
19. Rusinov V.L., Sapozhnikova I.M., Ulomskii E.N. et al. Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine-containing proteins. Chemistry of Heterocyclic Compounds. 2015;51(3):275–280. DOI: 10.1007/s10593-015-1695-4.
20. Чупахин О.Н., Русинов В.Л., Уломский Е.Н. и др. Способ получения натриевой соли 2-метилтио-6-нитро-1,2-4-триазоло[5,1-с]-1,2,4-триазин-7-она, дигидрата, обладающей противовирусной активностью. Патент RU2343154C2. Опубл. 10.01.2009. [Chupakhin O.N., Rusinov V.L., Ulomskij E.N. et al. 2-Methylthio-6-nitro-1,2,4-triazolo[5,1-c]-1,2,4-triazine-7(4H)-one sodium salt dehydrate possessing antiviral activity. Patent RU2343154C2. Published 01.10.2009 (in Russ.)].
21. Wu X., Yu K., Wang Y. et al. Efficacy and safety of triazavirin. Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial. Engineering (Beijing). 2020;6(10):1185–1191. DOI: 10.1016/j.eng.2020.08.011.
22. Сабитов А.У., Белоусов В.В., Един А.С. и др. Практический опыт применения препарата риамиловир в лечении пациентов с COVID-19 средней степени тяжести. Антибиотики и химиотерапия. 2020;65(7–8):27–30. DOI: 10.37489/0235-2990-2020-65-7-8-27-30. [Sabitov A.U., Belousov V.V., Odin A.S. et al. Practical experience of using the drug Riamilovir in the treatment of patients with COVID-19 of moderate severity. Antibiotiki i khimioterapiya. 2020;65(7–8):27–30 (in Russ.)]. DOI: 10.37489/0235-2990-2020-65-7-8-27-30.
23. Сабитов А.У., Сорокин П.В., Дашутина С.Ю. Эффективность и безопасность применения препарата Риамиловир в лечении пациентов с COVID-19. Антибиотики и химиотерапия. 2021;66(1-2):35–37. DOI: 10.37489/0235-2990-2021-66-1-2-33-37. [Sabitov А.U., Sorokin Р.V., Dashutina S.U. The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19. Antibiotics and Chemotherapy. 2021;66(1-2):35–37 (in Russ.)]. DOI: 10.37489/0235-2990-2021-66-1-2-33-37.
24. Сабитов А.У., Сорокин П.В., Дашутина С.Ю. Опыт профилактического применения препарата Риамиловир в очагах коронавирусной инфекции (COVID-19). Терапевтический архив. 2021;93(4):435–439. DOI: 10.26442/00403660.2021.04.200751. [Sabitov A.U., Sorokin P.V., Dashutina S.Yu. Experience of the preventive use of the drug Riamilovir in the foci of coronavirus infection (COVID-19) Terapevticheskii Arkhiv (Ter Arkh.). 2021;93(4):435–43 (in Russ.)]. DOI: 10.26442/00403660.2021.04.200751.
25. Анциферов М.Б., Аронов Л.С., Белевский А.С. и др. Клинический протокол лечения больных новой коронавирусной инфекцией (COVID-19), находящихся на стационарном лечении в медицинских организациях государственной системы здравоохранения города Москвы. Под ред. А.И. Хрипуна. М.: ГБУ «НИИОЗММ ДЗМ»; 2020. [Antsiferov M.B., Aronov L.S., Belevsky A.S. and others. Clinical protocol for the treatment of patients with a new coronavirus infection (COVID-19) undergoing inpatient treatment in medical organizations of the state healthcare system of the city of Moscow. Khripun A.I., ed. M.: State Budgetary Institution "NIIOZMM DZM"; 2020 (in Russ.)].
26. Мальцев О.В., Касьяненко К.В., Козлов К.В. и др. Перспективы использования нуклеозидного аналога риамиловира в лечении пациентов с инфекцией, вызванной SARS-CoV-2. Терапевтический архив. 2022;94(10):1171–1176. DOI: 10.26442/00403660.2022.10.201920. [Maltsev O.V., Kasyanenko K.V., Kozlov K.V. et al. Prospects of using the nucleoside analogue riamilovir in patients with SARS-CoV-2 infection. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(10):1171–1176 (in Russ.)]. DOI: 10.26442/00403660.2022.10.201920.
27. Касьяненко К.В., Мальцев О.В., Козлов К.В. и др. Клиническая эффективность и безопасность применения Риамиловира при лечении пациентов с инфекцией, вызванной SARS-CoV-2. Антибиотики и химиотерапия. 2020;65(11-12):16–21. [Kasyanenko K.V., Maltsev O.V., Kozlov K.V. et al. Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection. Antibiotics and Chemotherapy. 2020;65(11–12):16–21 (in Russ.)]. DOI: 10.37489/0235-2990-2020-65-11-12-16-21.
28. Касьяненко К.В., Козлов К.В., Мальцев О.В. и др. Оценка эффективности риамиловира в комплексной терапии больных COVID-19. Терапевтический архив. 2021;93(3):292–296. DOI: 10.26442/00403660.2021.03.200719. [Kasyanenko K.V., Kozlov K.V., Maltsev O.V. et al. Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19. Terapevticheskii Arkhiv (Ter Arkh). 2021;93(3):290–294 (in Russ.)]. DOI: 10.26442/00403660.2021.03.200719.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
